CVS Health announced plans to split into two publicly traded companies by the first half of 2028, separating its retail pharmacy business from its insurance unit, Aetna, and pharmacy benefit manager, Caremark. This move follows a turnaround effort that has strengthened both sides of the business and marks a shift from a breakup idea considered but rejected in 2024. CVS now believes both businesses can independently succeed, helped by improved profitability in retail and enhanced performance by Aetna despite ongoing high medical costs in Medicare Advantage.

Since CEO David Joyner took over in 2024, CVS has executed a rigorous $2 billion cost-cutting and restructuring plan, including closing stores and reducing Medicare Advantage expenses. These efforts have contributed to eight consecutive quarters of earnings beats and rising guidance, with the company forecasting operating cash flow of at least $15.5 billion in 2026, a nearly 70% increase from 2024. Joyner stressed that the decision to separate is driven by strength, giving each business more focus and flexibility rather than distress.

The retail pharmacy segment benefits from a changing competitive landscape with rivals like Walgreens and Rite Aid scaling back, allowing CVS to gain market share. Changes to its pharmacy reimbursement model have helped stabilize profits despite the segment’s traditionally low margins. However, analysts caution that the retail business remains vulnerable to consumer shifts and competition from online pharmacies. Meanwhile, Aetna has improved its handling of medical costs by exiting unprofitable markets and emphasizing value-based care, strengthening its insurance operations.

Regulatory pressures—especially on Caremark’s pharmacy benefit management—add complexity to the split, as some states debate laws banning combined ownership of pharmacies and PBMs. CVS insists the breakup is not due to regulatory issues but strategic focus. While Aetna and Caremark will stay together with specialty pharmacy and primary care services, the retail pharmacy will operate independently. Key synergies will be maintained through commercial agreements, though analysts note challenges remain, particularly around preserving competitive advantages and managing future business relationships under separate ownership.